Aminoasit Metabolizması Bozuklukları ve Görüntüleme Bulguları

Soylu Üstkoyuncu P. Aminoasit Metabolizması Bozuklukları. Kumandaş S ve Canpolat M (editörler). Temel Pediatrik Nöroloji. Tanı ve Tedavi. 2. Cilt. Bölüm 74. 1125-85.

Wasim M, Awan FR, Khan HN, Tawab A, Iqbal M, Ayesha H. Aminoacidopathies: Prevalence, Etiology, Screening, and Treatment Options. Biochem Genet. 2018; 56(1-2):7-21.

Coşkun T, Çoker M, Mungan NÖ, Gökmen Özel H, Sivri HS. Recommendations on phenylketonuria in Turkey. The Turkish Journal of Pediatrics 2022; 64: 413-34.

van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017; 12(1):162.

T.C. Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu. Çocuk ve Ergen Sağlığı Daire Başkanlığı. Yenidoğan Tarama Programı. 2018.

Burgard P, Lachmann RH, Walter J. Hyperphenylalaninaemia. In: Saudubray JM, Baumgartner MR, Walter J, eds. Inborn Metabolic Diseases. Diagnosis and Treatment, 6th ed. Berlin Heidelberg: Springer-Verlag; 2016: 252–64.

van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. Nat Rev Dis Primers. 2021; 7(1): 36.

Reddy N, Calloni SF, Vernon HJ, Boltshauser E, Huisman TAGM, Soares BP. Neuroimaging Findings of Organic Acidemias and Aminoacidopathies. Radiographics. 2018;38(3):912-31

Öztürk Hişmi B, Akın BK. Fenilketonüri ve Beslenme Tedavisi. Kalıtsal Metabolik Hastalıklarda Beslenme Tedavisi. Eminoglu FT, Haspolat YK, Çeltik C, Çarman KB, Akbulut UE, Taş T (editörler). 159-200.

Lindner M, Gramer G, Garbade SF, Burgard P. Blood phenylalanine concentrations in patients with PAH-deficient hyperphenylalaninaemia off diet without and with three different single oral doses of tetrahydrobiopterin: assessing responsiveness in a model of statistical process control. J Inherit Metab Dis 2009; 32(4):514-22.

Vonada A, Wakefield L, Martinez M, Harding CO, Grompe M, Tiyaboonchai A. Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation. Hepatology. 2024; 79(5):1088-97.

Sarkissian CN, Gamez A, Wang L, et al. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc Natl Acad Sci USA 2008; 105(52):20894-9.

Berger V, Larondelle Y, Trouet A, Schneider YJ. Transport mechanisms of the large neutral amino Acid L-phenylalanine in the human intestinal epithelial caco-2 cell line. J Nutr 2000; 130(11):2780-8.

Pietz J, Kreis R, Rupp A, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest. 1999; 103(8):1169–78

Pena MJ, Pinto A, Daly A, et al. The Use of Glycomacropeptide in Patients with Phenylketonuria: A Systematic Review and Meta-Analysis. Nutrients. 2018; 10(11):1794.

Wiedemann A, Oussalah A, Jeannesson É, Guéant JL, Feillet F. Phenylketonuria, from diyet to gene therapy. Med Sci (Paris). 2020; 36(8-9):725-34.

Opladen T, López-Laso E, Cortès-Saladelafont E, et al. Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. Orphanet J Rare Dis. 2020; 15(1):126.

Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab. 2011; 104:2-9.

Ergul Bozaci A, Er E, Yazici H, et al. Tetrahydrobiopterin deficiencies: Lesson from clinical experience. JIMD Rep 2021; 59(1):42-51.

Niu DM. Disorders of BH4 metabolism and the treatment of patients with 6-pyruvoyl-tetrahydropterin synthase deficiency in Taiwan. Brain & Development. 2011; 33: 847–55.

21.Coskun T, Ozalp I, Tokatlı A, Blau N, Niederwieser A. Hyperphenylalaninaemia due to tetrahydrobiopterin deficiency: a report of 16 cases. J Inherit Metab Dis. 1993; 16(3):605-7.

Almannai M, Felemban R, Saleh MA, et al. 6-Pyruvoyltetrahydropterin Synthase Deficiency: Review and Report of 28 Arab Subjects Pediatric Neurology 2019, 96: 40-7.

Ferre S, de Baaij JH, Ferreira P, et al. Mutations in PCBD1 cause hypomagnesemia and renal magnesium wasting. J Am Soc Nephrol. 2014; 25(3):574–86

Kuseyri Hübschmann O, Mohr A, Friedman J et al. Brain MR patterns in inherited disorders of monoamine neurotransmitters: An analysis of 70 patients. J Inherit Metab Dis. 2021;44(4):1070-82.

Engin Erdal A, Kıreker Köylü O, Ceylan AC, Kasapkara ÇS, Tunçez E, Topçu M. Sepiapterin Reductase Deficiency Misdiagnosed as Neurological Sequelae of Meningitis. Mol Syndromol. 2024;15(2):130-5

Wang L, Yu WM, He C, et al. Long-term outcome and neuroradiological findings of 31 patients with 6- pyruvoyltetrahydropterin synthase deficiency. J Inherit Metab Dis. 2006; 29(1): 127–34

Coskun T, Besim A, Ozalp I, Eryilmaz M. Intracranial calcification in dihydropteridine reductase deficiency. Turk J Pediatr. 1990; 32(4):259–64

Friedman J. Sepiapterin Reductase Deficiency.2015 Jul 1. In: Adam MP, Feldman J, Mirzaa GM, et al. editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.

Blau N, Bonafé L, Thöny B. Tetrahydrobiopterin deficiencies without hyperphenylalaninemia: diagnosis and genetics of dopa-responsive dystonia and sepiapterin reductase deficiency. Mol Genet Metab. 2001; 74(1-2):172-85.

Blau N, Martinez A, Hoffmann GF, Thony B. DNAJC12 deficiency: A new strategy in the diagnosis of hyperphenylalaninemias. Mol Genet Metab. 2018; 123(1):1–5.

Hsu RH, Lee NC, Chen HA, Hwu WL, Chang TM, Chien YH. Late-onset symptomatic hyperprolactinemia in 6-pyruvoyl-tetrahydropterin synthase deficiency. Orphanet J Rare Dis 2023; 18(1):351.

Ye J, Yang Y, Yu W, et al. Demographics, diagnosis and treatment of 256 patients with tetrahydrobiopterin deficiency in mainland China: results of a retrospective, multicentre study. J Inherit Metab Dis. 2013; 36(5):893–901

Strauss KA, Puffenberger EG, Carson VJ. Maple Syrup Urine Disease. 2006 Jan 30 [Updated 2020 Apr 23]. In: Adam MP, Feldman J, Mirzaa GM, et al. editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.

Nellis MM, Kasinski A, Carlson M, et al. Relationship of causative genetic mutations in maple syrup urine disease with their clinical expression. Mol Genet Metab. 2003:80:189-95.

Blackburn PR, Gass JM, Vairo FPE, et al. Maple syrup urine disease: mechanisms and management. Appl Clin Genet. 2017; 10: 57-66.

Strauss KA, Carson VJ, Soltys K, et al. Branched-chain α-ketoacid dehydrogenase deficiency (maple syrup urine disease): Treatment, biomarkers, and outcomes. Mol Genet Metab. 2020; 129(3):193-206

Mohamed MM, Bakheet MA, Magdy RM, El-Abd HS, Alam-Eldeen MH, Abo-Haded HM. The clinico-radiological findings of MSUD in a group of Egyptian children: Contribution to early diagnosis and outcome. Mol Genet Genomic Med. 2021; 9(10):e1790.

Zimmerman RA, Wang ZJ, Berry GT, Kaplan PB, Kaye EM. MR diffusion imaging and MR spectroscopy of maple syrup urine disease during acute metabolic decompensation. Neuroradiology 2003;45(6):393–9.

Rostampour N, Dalili S, Moravej H, et al. Comprehensive Iranian guidelines for the diagnosis and management of maple syrup urine disease: an evidence- and consensus- based approach. Orphanet J Rare Dis. 2025;20(1):8.

Schiff M, de Baulny HO, Dionisi-Vici C. Branched-chain Organic Acidurias /Acidaemias. In: Saudubray JM, Baumgartner MR, Walter J, eds. Inborn Metabolic Diseases. Diagnosis and Treatment, 6th ed. Berlin Heidelberg: Springer-Verlag; 2016: 277-94

de Lonlay P, Posset R, Mütze U, et al. Real-world management of maple syrup urine disease (MSUD) metabolic decompensations with branched chain amino acid-free formulas in France and Germany: A retrospective observational study. JIMD Rep. 2021; 59(1):110-19.

Scott AI, Cusmano-Ozog K, Enns GM, Cowan TM. Correction of hyperleucinemia in MSUD patients on leucine-free dietary therapy. Mol Genet Metab. 2017; 122(4):156-59.

Falah N, Pendyal S, Sasannejad C, et al. The interplay of psychosis and non-compliance with fatal outcome in an adult with MSUD. Am J Med Genet A. 2024; 194(9): e63637

Deon M, Guerreiro G, Girardi J, Ribas G, Vargas CR. Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation. Int J Dev Neurosci. 2023; 83(6):489-504.

Vasudevan AK, Shanmugam N, Rammohan A, et al. Long-Term Amino Acid Homeostasis, Neurodevelopmental and Growth Profiles Following Liver Transplantation in Maple Syrup Urine Disease.Pediatr Transplant. 2024;28(6): e14845.

Chinsky JM, Singh R, Ficicioglu C, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017; 19(12).

Grenier A, Lescault A, Laberge C, Gagne R, Mamer O. Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia. Clin Chim Acta. 1982; 123:93–9.

Sniderman King L, Trahms C, Scott CR. Tyrosinemia type I. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds). Gene Reviews: Seattle, WA, 1993.

Jorquera R, Tanguay RM. The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. Biochem BiophysRes Commun 1997; 232:42–8.

Chakrapani A, Gissen P, McKiernan P. Disorders of Tyrosine Metabolism in: Saudubray JM, Baumgartner MR, Walter J, eds. Inborn Metabolic Diseases. Diagnosis and Treatment, 6th ed. Berlin Heidelberg: Springer-Verlag; 2016: 266–75

Gokay S, Soylu Ustkoyuncu P, Kardas, F, Kendirci M. The outcome of seven patients with hereditary tyrosinemia type 1. JPEM 2016; 29(10):1151-7

Aktuglu-Zeybek C, Kiykim E, Cansever MS. Hereditary Tyrosinemia Type 1 in Turkey. Adv Exp Med Biol. 2017; 959:157-172.

Zeybek AC, Kiykim E, Soyucen E, et al. Hereditary tyrosinemia type 1 in Turkey: twenty-year single-center experience. Pediatr Int. 2015; 57(2):281-9.

Shaikh S, Qureshi A, Faiq SM. Revisiting hereditary tyrosinemia Type 1-spectrum of radiological findings. BJR Case Rep. 2018;5(2):20180001

De Jesus VR, Adam BW, Mandel D, Cuthbert CD, Matern D. Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs. Mol Genet Metab 2014; 113:67–75

Larochelle J, Alvarez F, Bussières JF, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Mol Genet Metab 2012; 107:49–54.

van Ginkel WG, Rodenburg IL, Harding CO, et al. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1. Paediatr Drugs. 2019; 21(6):413-26.

de Laet C, Dionisi-Vici C, Leonard JV, et al. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis 2013; 8:8

Lewis V, Rohr F, Van Calcar S. Protocol 3—Tyrosinemia Types 1a and 1b Nutrition Support Protocols, 4th edn. Ross Products Division: Columbus, OH, 2001:49–62

Kehar M, Sen Sarma M, Seetharaman J, Jimenez Rivera C, Chakraborty P. Decoding hepatorenal tyrosinemia type 1: Unraveling the impact of early detection, NTBC, and the role of liver transplantation. Can Liver J. 2024; 7(1):54-63.

Pohorecka M, Biernacka M, Jakubowska-Winecka A, et al. Behavioral and intellectual functioning in patients with tyrosinemia type I. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 2012;18:96–100.

Bendadi F, de Koning TJ, Visser G, et al. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone. J Pediatr. 2014; 164: 398–401

Beyzaei Z, Dehdhani SM, Geramizadeh B. Tyrosinemia Type II. 2024 In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.

Peña-Quintana L, Scherer G, Curbelo-Estévez ML, et al. Tyrosinemia type II: Mutation update, 11 novel mutations and description of 5 independent subjects with a novel founder mutation. Clin Genet. 2017; 92(3):306-17.

Mohite AA, Abbott J. Photophobia accompanied by painful plantar punctate hyperkeratotic patches: Tyrosinemia type 2. Indian J Ophthalmol. 2018; 66(3):449.

Majtan T, Kožich V, Kruger WD. Recent therapeutic approaches to cystathionine beta-synthase-deficient homocystinuria Br J Pharmacol. 2023; 180(3): 264–78.

Sacharow SJ, Picker JD, Levy HL. Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency. 2004 Jan 15 [updated 2017 May 18]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. Gene Reviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.

Truitt C, Hoff WD, Deole R. Health Functionalities of Betaine in Patients with Homocystinuria. Front Nutr. 2021; 8: 690359.

Gan-Schreier H, Kebbewar M, Fang-Hoffmann J, et al. Newborn population screening for classic homocystinuria by determination of total homocysteine from Guthrie cards. J Pediatr. 2010; 156:427–32.

Koye A, Nilsson M, Epstein D, Oscarson M, Teär Fahnehjelm K. Visual functions, ocular characteristics and visual quality of life in patients with homocystinuria. Ophthalmic Genet. 2024; 45(4):343-350

Jain M, Shah M, Thakker KM, et al. High clinical burden of classical homocystinuria in the United States: a retrospective analysis. Orphanet J Rare Dis. 2025;20(1):37

Reddy N, Calloni SF, Vernon HJ, Boltshauser E, Huisman TAGM, Soares BP. Neuroimaging Findings of Organic Acidemias and Aminoacidopathies. Radiographics. 2018;38(3):912-31.

Majtan T, Krijt J, Sokolová J, et al. Biogenesis of Hydrogen Sulfide and Thioethers by Cystathionine Beta-Synthase. Antioxid Redox Signal. 2018; 28(4):311-23.

Morris AAM, Kožich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine β-synthase deficiency. J Inherit Metab Dis. 2017; 40:49–74.

Mudd SH, Glenn B, Wagner C, et al. SAdenosylhomocysteine (AdoHcy) hydrolase deficiency in a Croatian boy. J Inherit Metab Dis. 2003; 26 Suppl 1:15A.

Barić I, Staufner C, Augoustides-Savvopoulou P, et al. Consensus recommendations for the diagnosis, treatment and follow-up of inherited methylation disorders. J Inherit Metab Dis. 2017; 40:5–20

Mudd SH. Hypermethioninemias of genetic and non-genetic origin. A review. Am J Med Genet C Semin Med Genet? 2011; 157C:3–32.

Yap S, Rushe H, Howard PM, Naughten ER. The intellectual abilities of early-treated individuals with pyridoxine-nonresponsive homocystinuria due to cystathionine β-synthase deficiency. J Inherit Metab Dis. 2001b; 24:437–47.

Yaghmai R, Kashani AH, Geraghty MT, et al Progressive cerebral edema associated with high methionine levels and betaine therapy in a patient with cystathionine β-synthase (CBS) deficiency. Am J Med Genet. 2002; 108:57–63.

Kožich V, Majtan T. Inherited disorders of sulfur amino acid metabolism: recent advances in therapy. Curr Opin Clin Nutr Metab Care. 2021; 24(1):62-70.

Bublil EM, Majtan T. Classical homocystinuria: From cystathionine beta-synthase deficiency to novel enzyme therapies. Biochimie. 2020; 173:48-56.

Johannes L, Fu CY, Schwarz G. Molybdenum Cofactor Deficiency in Humans. Molecules. 2022; 27: 6896.

Schwahn BC, van Spronsen F, Misko A, et al. Consensus guidelines for the diagnosis and management of isolated sulfite oxidase deficiency and molybdenum cofactor deficiencies. J Inherit Metab Dis. 2024; 47(4):598-623.

Durmaz MS, Özbakır B. Molybdenum cofactor deficiency: Neuroimaging findings. Radiol Case Rep. 2018 Mar 22; 13(3):592-95.

Spiegel R, Schwahn BC, Squires L, Confer N. Molybdenum cofactor deficiency: A natural history. J Inherit Metab Dis. 2022; 45(3):456-69.

Vijayakumar K, Gunny R, Grunewald S, et al. Clinical neuroimaging features and outcome in molybdenum cofactor deficiency. Pediatr Neurol. 2011;45(4):246-52

Kumar A, Dejanovic B, Hetsch F, et al. S-Sulfocysteine/NMDA Receptor-Dependent Signaling Underlies Neurodegeneration in Molybdenum Cofactor Deficiency. J. Clin. Investig. 2017; 127: 4365-78.

Footitt EJ, Heales SJ, Mills PB, Allen GFG, Oppenheim M, Clayton PT. Pyridoxal 5-Phosphate in Cerebrospinal Fluid; Factors Affecting Concentration. J. Inherit. Metab. Dis. 2011; 34: 529-38.

Schwahn BC, van Spronsen FJ, Belaidi AA, et al. Efficacy and Safety of Cyclic Pyranopterin Monophosphate Substitution in Severe Molybdenum Cofactor Deficiency Type A: A Prospective Cohort Study. Lancet 2015; 386:1955-63.

Nonketotic Hyperglycinemia.Van Hove JLK, Coughlin C II, Swanson M, Hennermann JB.2002 Nov 14 [updated 2019 May 23]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.

Van Hove JLK, Hennermann JB, Coughlin II CR. Nonketotic Hyperglycinemia (Glycine Encephalopathy) and Lipoate Deficiency Disorders. In: Saudubray JM, Baumgartner MR, Walter J, eds. Inborn Metabolic Diseases. Diagnosis and Treatment, 6th ed. Berlin Heidelberg: Springer-Verlag; 2016: 350-6.

Coughlin CR 2nd, Swanson MA, Kronquist K, et al. The genetic basis of classical nonketotic hyperglycinemia due to mutations in GLDC and AMT. Genet Med. 2017; 19:104–11

Kikuchi G, Motokawa Y, Yoshida T, Hiraga K. Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia. Proc Jpn Acad Ser B Phys Biol Sci. 2008; 84(7):246-63.

Hennermann JB, Berger JM, Grieben U, Scharer G, Van Hove JL. Prediction of long-term outcome in glycine encephalopathy: a clinical survey. J Inherit Metab Dis. 2012; 35: 253–61.

Van Hove JLK, Kishnani PS, Demaerel P, et al. Acute hydrocephalus in nonketotic hyperglycinemia. Neurology. 2000; 54:754–6

Van Hirtum LDFM, Van Damme T, Van Hove JLK, Steyaert JG. The behavioral phenotype of children and adolescents with attenuated non-ketotic hyperglycinemia, intermediate to good subtype. Orphanet J Rare Dis. 2024;19(1):150.

Mayr JA, Feichtinger RG, Tort F, Ribes A, Sperl W. Lipoic acid biosynthesis defects. J Inherit Metab Dis. 2014; 37(4):553-63.

Viola A, Chabrol B, Nicoli F, Confort-Gouny S, Viout P, Cozzone PJ. Magnetic resonance spectroscopy study of glycine pathways in nonketotic hyperglycinemia. Pediatr Res 2002;52(2):292–300.

Aliefendioğlu D, Tana Aslan Ay, Coşkun T, Dursun A, Cakmak FN, Kesimer M. Transient nonketotic hyperglycinemia: two case reports and literature review. Pediatr Neurol. 2003; 28(2):151-5.

Van Hove JLK, Vande Kerckhove K, Hennermann JB, et al. Benzoate treatment and the glycine index in nonketotic hyperglycinaemia. J Inherit Metab Dis. 2005; 28:651–63.

Nowak M, Chuchra P, Paprocka JJ. Nonketotic Hyperglycinemia: Insight into Current Therapies. Clin Med. 2022; 11(11):3027.

Van Hove JLK. The role of NMDA-receptor type glutamatergic antagonists’ dextromethorphan or ketamine in the treatment of nonketotic hyperglycinemia: A critical reassessment. Mol Genet Metab. 2024; 143(3):108594.

Scholl-Bürgi S, Höller A, Pichler K, Michel M, Haberlandt E, Karall D. Ketogenic diets in patients with inherited metabolic disorders. J Inherit Metab Dis. 2015; 38(4):765-73.